Global Phenylketonuria

Phenylketonuria Comprehensive Study by Type (Classic, Mild, Benign), Treatment (Drug Therapy, Dietary Therapy, Gene Therapy), Test (Diagnostic Test, Screening Test), End User (Household, Hospital, Others) Players and Region - Global Market Outlook to 2028

Phenylketonuria Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Phenylketonuria
Phenylketonuria (PKU) is an inborn error of metabolism that results in decreased metabolism of the amino acid phenylalanine. Untreated PKU can lead to intellectual disability, seizures, behavioral problems, and mental disorders. It may also result in a musty smell and lighter skin. Babies born to mothers who have poorly treated PKU may have heart problems, a small head, and low birth weight.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Phenylketonuria market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Agios Pharmaceuticals Inc. (United States), BioMarin Pharmaceutical Inc. (United States), Nestlé Health Science (Switzerland), American Gene Technologies International Inc (United States), Mead Johnson & Company, LLC. (United States), Danone Nutricia (Netherlands), Ajinomoto Cambrooke, Inc. (United States), Dr. Schär (Italy), Promin Metabolics (United States) and PKU Perspectives (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Censa Pharmaceuticals Inc. (United States) and Erytech Pharma SA (France).

Segmentation Overview
AMA Research has segmented the market of Global Phenylketonuria market by Type (Classic, Mild and Benign) and Region.



On the basis of geography, the market of Phenylketonuria has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Drug Therapy will boost the Phenylketonuria market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Test, the sub-segment i.e. Diagnostic Test will boost the Phenylketonuria market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Household will boost the Phenylketonuria market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers:
Rising Number of Newborn Who Suffers from the Phenylketonuria and Increasing Healthcare Spending and Rising Healthcare Infrastructure in Developing Economies

Restraints:
Issues Related to Screening of Newborn are hindering the Market

Opportunities:
Increasing Awareness about the Phenylketonuria Disease among the People Creates the Opportunities for Market



About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Classic
  • Mild
  • Benign
By Treatment
  • Drug Therapy
  • Dietary Therapy
  • Gene Therapy

By Test
  • Diagnostic Test
  • Screening Test

By End User
  • Household
  • Hospital
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Newborn Who Suffers from the Phenylketonuria
      • 3.2.2. Increasing Healthcare Spending and Rising Healthcare Infrastructure in Developing Economies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Phenylketonuria, by Type, Treatment, Test, End User and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Phenylketonuria (Value)
      • 5.2.1. Global Phenylketonuria by: Type (Value)
        • 5.2.1.1. Classic
        • 5.2.1.2. Mild
        • 5.2.1.3. Benign
      • 5.2.2. Global Phenylketonuria by: Treatment (Value)
        • 5.2.2.1. Drug Therapy
        • 5.2.2.2. Dietary Therapy
        • 5.2.2.3. Gene Therapy
      • 5.2.3. Global Phenylketonuria by: Test (Value)
        • 5.2.3.1. Diagnostic Test
        • 5.2.3.2. Screening Test
      • 5.2.4. Global Phenylketonuria by: End User (Value)
        • 5.2.4.1. Household
        • 5.2.4.2. Hospital
        • 5.2.4.3. Others
      • 5.2.5. Global Phenylketonuria Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Phenylketonuria (Price)
      • 5.3.1. Global Phenylketonuria by: Type (Price)
  • 6. Phenylketonuria: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Agios Pharmaceuticals Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BioMarin Pharmaceutical Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Nestlé Health Science (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. American Gene Technologies International Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Mead Johnson & Company, LLC. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Danone Nutricia (Netherlands)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ajinomoto Cambrooke, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Dr. Schär (Italy)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Promin Metabolics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. PKU Perspectives (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Phenylketonuria Sale, by Type, Treatment, Test, End User and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Phenylketonuria (Value)
      • 7.2.1. Global Phenylketonuria by: Type (Value)
        • 7.2.1.1. Classic
        • 7.2.1.2. Mild
        • 7.2.1.3. Benign
      • 7.2.2. Global Phenylketonuria by: Treatment (Value)
        • 7.2.2.1. Drug Therapy
        • 7.2.2.2. Dietary Therapy
        • 7.2.2.3. Gene Therapy
      • 7.2.3. Global Phenylketonuria by: Test (Value)
        • 7.2.3.1. Diagnostic Test
        • 7.2.3.2. Screening Test
      • 7.2.4. Global Phenylketonuria by: End User (Value)
        • 7.2.4.1. Household
        • 7.2.4.2. Hospital
        • 7.2.4.3. Others
      • 7.2.5. Global Phenylketonuria Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Phenylketonuria (Price)
      • 7.3.1. Global Phenylketonuria by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Phenylketonuria: by Type(USD Million)
  • Table 2. Phenylketonuria Classic , by Region USD Million (2017-2022)
  • Table 3. Phenylketonuria Mild , by Region USD Million (2017-2022)
  • Table 4. Phenylketonuria Benign , by Region USD Million (2017-2022)
  • Table 5. Phenylketonuria: by Treatment(USD Million)
  • Table 6. Phenylketonuria Drug Therapy , by Region USD Million (2017-2022)
  • Table 7. Phenylketonuria Dietary Therapy , by Region USD Million (2017-2022)
  • Table 8. Phenylketonuria Gene Therapy , by Region USD Million (2017-2022)
  • Table 9. Phenylketonuria: by Test(USD Million)
  • Table 10. Phenylketonuria Diagnostic Test , by Region USD Million (2017-2022)
  • Table 11. Phenylketonuria Screening Test , by Region USD Million (2017-2022)
  • Table 12. Phenylketonuria: by End User(USD Million)
  • Table 13. Phenylketonuria Household , by Region USD Million (2017-2022)
  • Table 14. Phenylketonuria Hospital , by Region USD Million (2017-2022)
  • Table 15. Phenylketonuria Others , by Region USD Million (2017-2022)
  • Table 16. South America Phenylketonuria, by Country USD Million (2017-2022)
  • Table 17. South America Phenylketonuria, by Type USD Million (2017-2022)
  • Table 18. South America Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 19. South America Phenylketonuria, by Test USD Million (2017-2022)
  • Table 20. South America Phenylketonuria, by End User USD Million (2017-2022)
  • Table 21. Brazil Phenylketonuria, by Type USD Million (2017-2022)
  • Table 22. Brazil Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 23. Brazil Phenylketonuria, by Test USD Million (2017-2022)
  • Table 24. Brazil Phenylketonuria, by End User USD Million (2017-2022)
  • Table 25. Argentina Phenylketonuria, by Type USD Million (2017-2022)
  • Table 26. Argentina Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 27. Argentina Phenylketonuria, by Test USD Million (2017-2022)
  • Table 28. Argentina Phenylketonuria, by End User USD Million (2017-2022)
  • Table 29. Rest of South America Phenylketonuria, by Type USD Million (2017-2022)
  • Table 30. Rest of South America Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 31. Rest of South America Phenylketonuria, by Test USD Million (2017-2022)
  • Table 32. Rest of South America Phenylketonuria, by End User USD Million (2017-2022)
  • Table 33. Asia Pacific Phenylketonuria, by Country USD Million (2017-2022)
  • Table 34. Asia Pacific Phenylketonuria, by Type USD Million (2017-2022)
  • Table 35. Asia Pacific Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 36. Asia Pacific Phenylketonuria, by Test USD Million (2017-2022)
  • Table 37. Asia Pacific Phenylketonuria, by End User USD Million (2017-2022)
  • Table 38. China Phenylketonuria, by Type USD Million (2017-2022)
  • Table 39. China Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 40. China Phenylketonuria, by Test USD Million (2017-2022)
  • Table 41. China Phenylketonuria, by End User USD Million (2017-2022)
  • Table 42. Japan Phenylketonuria, by Type USD Million (2017-2022)
  • Table 43. Japan Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 44. Japan Phenylketonuria, by Test USD Million (2017-2022)
  • Table 45. Japan Phenylketonuria, by End User USD Million (2017-2022)
  • Table 46. India Phenylketonuria, by Type USD Million (2017-2022)
  • Table 47. India Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 48. India Phenylketonuria, by Test USD Million (2017-2022)
  • Table 49. India Phenylketonuria, by End User USD Million (2017-2022)
  • Table 50. South Korea Phenylketonuria, by Type USD Million (2017-2022)
  • Table 51. South Korea Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 52. South Korea Phenylketonuria, by Test USD Million (2017-2022)
  • Table 53. South Korea Phenylketonuria, by End User USD Million (2017-2022)
  • Table 54. Taiwan Phenylketonuria, by Type USD Million (2017-2022)
  • Table 55. Taiwan Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 56. Taiwan Phenylketonuria, by Test USD Million (2017-2022)
  • Table 57. Taiwan Phenylketonuria, by End User USD Million (2017-2022)
  • Table 58. Australia Phenylketonuria, by Type USD Million (2017-2022)
  • Table 59. Australia Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 60. Australia Phenylketonuria, by Test USD Million (2017-2022)
  • Table 61. Australia Phenylketonuria, by End User USD Million (2017-2022)
  • Table 62. Rest of Asia-Pacific Phenylketonuria, by Type USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Phenylketonuria, by Test USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Phenylketonuria, by End User USD Million (2017-2022)
  • Table 66. Europe Phenylketonuria, by Country USD Million (2017-2022)
  • Table 67. Europe Phenylketonuria, by Type USD Million (2017-2022)
  • Table 68. Europe Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 69. Europe Phenylketonuria, by Test USD Million (2017-2022)
  • Table 70. Europe Phenylketonuria, by End User USD Million (2017-2022)
  • Table 71. Germany Phenylketonuria, by Type USD Million (2017-2022)
  • Table 72. Germany Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 73. Germany Phenylketonuria, by Test USD Million (2017-2022)
  • Table 74. Germany Phenylketonuria, by End User USD Million (2017-2022)
  • Table 75. France Phenylketonuria, by Type USD Million (2017-2022)
  • Table 76. France Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 77. France Phenylketonuria, by Test USD Million (2017-2022)
  • Table 78. France Phenylketonuria, by End User USD Million (2017-2022)
  • Table 79. Italy Phenylketonuria, by Type USD Million (2017-2022)
  • Table 80. Italy Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 81. Italy Phenylketonuria, by Test USD Million (2017-2022)
  • Table 82. Italy Phenylketonuria, by End User USD Million (2017-2022)
  • Table 83. United Kingdom Phenylketonuria, by Type USD Million (2017-2022)
  • Table 84. United Kingdom Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 85. United Kingdom Phenylketonuria, by Test USD Million (2017-2022)
  • Table 86. United Kingdom Phenylketonuria, by End User USD Million (2017-2022)
  • Table 87. Netherlands Phenylketonuria, by Type USD Million (2017-2022)
  • Table 88. Netherlands Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 89. Netherlands Phenylketonuria, by Test USD Million (2017-2022)
  • Table 90. Netherlands Phenylketonuria, by End User USD Million (2017-2022)
  • Table 91. Rest of Europe Phenylketonuria, by Type USD Million (2017-2022)
  • Table 92. Rest of Europe Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 93. Rest of Europe Phenylketonuria, by Test USD Million (2017-2022)
  • Table 94. Rest of Europe Phenylketonuria, by End User USD Million (2017-2022)
  • Table 95. MEA Phenylketonuria, by Country USD Million (2017-2022)
  • Table 96. MEA Phenylketonuria, by Type USD Million (2017-2022)
  • Table 97. MEA Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 98. MEA Phenylketonuria, by Test USD Million (2017-2022)
  • Table 99. MEA Phenylketonuria, by End User USD Million (2017-2022)
  • Table 100. Middle East Phenylketonuria, by Type USD Million (2017-2022)
  • Table 101. Middle East Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 102. Middle East Phenylketonuria, by Test USD Million (2017-2022)
  • Table 103. Middle East Phenylketonuria, by End User USD Million (2017-2022)
  • Table 104. Africa Phenylketonuria, by Type USD Million (2017-2022)
  • Table 105. Africa Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 106. Africa Phenylketonuria, by Test USD Million (2017-2022)
  • Table 107. Africa Phenylketonuria, by End User USD Million (2017-2022)
  • Table 108. North America Phenylketonuria, by Country USD Million (2017-2022)
  • Table 109. North America Phenylketonuria, by Type USD Million (2017-2022)
  • Table 110. North America Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 111. North America Phenylketonuria, by Test USD Million (2017-2022)
  • Table 112. North America Phenylketonuria, by End User USD Million (2017-2022)
  • Table 113. United States Phenylketonuria, by Type USD Million (2017-2022)
  • Table 114. United States Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 115. United States Phenylketonuria, by Test USD Million (2017-2022)
  • Table 116. United States Phenylketonuria, by End User USD Million (2017-2022)
  • Table 117. Canada Phenylketonuria, by Type USD Million (2017-2022)
  • Table 118. Canada Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 119. Canada Phenylketonuria, by Test USD Million (2017-2022)
  • Table 120. Canada Phenylketonuria, by End User USD Million (2017-2022)
  • Table 121. Mexico Phenylketonuria, by Type USD Million (2017-2022)
  • Table 122. Mexico Phenylketonuria, by Treatment USD Million (2017-2022)
  • Table 123. Mexico Phenylketonuria, by Test USD Million (2017-2022)
  • Table 124. Mexico Phenylketonuria, by End User USD Million (2017-2022)
  • Table 125. Phenylketonuria: by Type(USD/Units)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Phenylketonuria: by Type(USD Million)
  • Table 137. Phenylketonuria Classic , by Region USD Million (2023-2028)
  • Table 138. Phenylketonuria Mild , by Region USD Million (2023-2028)
  • Table 139. Phenylketonuria Benign , by Region USD Million (2023-2028)
  • Table 140. Phenylketonuria: by Treatment(USD Million)
  • Table 141. Phenylketonuria Drug Therapy , by Region USD Million (2023-2028)
  • Table 142. Phenylketonuria Dietary Therapy , by Region USD Million (2023-2028)
  • Table 143. Phenylketonuria Gene Therapy , by Region USD Million (2023-2028)
  • Table 144. Phenylketonuria: by Test(USD Million)
  • Table 145. Phenylketonuria Diagnostic Test , by Region USD Million (2023-2028)
  • Table 146. Phenylketonuria Screening Test , by Region USD Million (2023-2028)
  • Table 147. Phenylketonuria: by End User(USD Million)
  • Table 148. Phenylketonuria Household , by Region USD Million (2023-2028)
  • Table 149. Phenylketonuria Hospital , by Region USD Million (2023-2028)
  • Table 150. Phenylketonuria Others , by Region USD Million (2023-2028)
  • Table 151. South America Phenylketonuria, by Country USD Million (2023-2028)
  • Table 152. South America Phenylketonuria, by Type USD Million (2023-2028)
  • Table 153. South America Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 154. South America Phenylketonuria, by Test USD Million (2023-2028)
  • Table 155. South America Phenylketonuria, by End User USD Million (2023-2028)
  • Table 156. Brazil Phenylketonuria, by Type USD Million (2023-2028)
  • Table 157. Brazil Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 158. Brazil Phenylketonuria, by Test USD Million (2023-2028)
  • Table 159. Brazil Phenylketonuria, by End User USD Million (2023-2028)
  • Table 160. Argentina Phenylketonuria, by Type USD Million (2023-2028)
  • Table 161. Argentina Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 162. Argentina Phenylketonuria, by Test USD Million (2023-2028)
  • Table 163. Argentina Phenylketonuria, by End User USD Million (2023-2028)
  • Table 164. Rest of South America Phenylketonuria, by Type USD Million (2023-2028)
  • Table 165. Rest of South America Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 166. Rest of South America Phenylketonuria, by Test USD Million (2023-2028)
  • Table 167. Rest of South America Phenylketonuria, by End User USD Million (2023-2028)
  • Table 168. Asia Pacific Phenylketonuria, by Country USD Million (2023-2028)
  • Table 169. Asia Pacific Phenylketonuria, by Type USD Million (2023-2028)
  • Table 170. Asia Pacific Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 171. Asia Pacific Phenylketonuria, by Test USD Million (2023-2028)
  • Table 172. Asia Pacific Phenylketonuria, by End User USD Million (2023-2028)
  • Table 173. China Phenylketonuria, by Type USD Million (2023-2028)
  • Table 174. China Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 175. China Phenylketonuria, by Test USD Million (2023-2028)
  • Table 176. China Phenylketonuria, by End User USD Million (2023-2028)
  • Table 177. Japan Phenylketonuria, by Type USD Million (2023-2028)
  • Table 178. Japan Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 179. Japan Phenylketonuria, by Test USD Million (2023-2028)
  • Table 180. Japan Phenylketonuria, by End User USD Million (2023-2028)
  • Table 181. India Phenylketonuria, by Type USD Million (2023-2028)
  • Table 182. India Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 183. India Phenylketonuria, by Test USD Million (2023-2028)
  • Table 184. India Phenylketonuria, by End User USD Million (2023-2028)
  • Table 185. South Korea Phenylketonuria, by Type USD Million (2023-2028)
  • Table 186. South Korea Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 187. South Korea Phenylketonuria, by Test USD Million (2023-2028)
  • Table 188. South Korea Phenylketonuria, by End User USD Million (2023-2028)
  • Table 189. Taiwan Phenylketonuria, by Type USD Million (2023-2028)
  • Table 190. Taiwan Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 191. Taiwan Phenylketonuria, by Test USD Million (2023-2028)
  • Table 192. Taiwan Phenylketonuria, by End User USD Million (2023-2028)
  • Table 193. Australia Phenylketonuria, by Type USD Million (2023-2028)
  • Table 194. Australia Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 195. Australia Phenylketonuria, by Test USD Million (2023-2028)
  • Table 196. Australia Phenylketonuria, by End User USD Million (2023-2028)
  • Table 197. Rest of Asia-Pacific Phenylketonuria, by Type USD Million (2023-2028)
  • Table 198. Rest of Asia-Pacific Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 199. Rest of Asia-Pacific Phenylketonuria, by Test USD Million (2023-2028)
  • Table 200. Rest of Asia-Pacific Phenylketonuria, by End User USD Million (2023-2028)
  • Table 201. Europe Phenylketonuria, by Country USD Million (2023-2028)
  • Table 202. Europe Phenylketonuria, by Type USD Million (2023-2028)
  • Table 203. Europe Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 204. Europe Phenylketonuria, by Test USD Million (2023-2028)
  • Table 205. Europe Phenylketonuria, by End User USD Million (2023-2028)
  • Table 206. Germany Phenylketonuria, by Type USD Million (2023-2028)
  • Table 207. Germany Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 208. Germany Phenylketonuria, by Test USD Million (2023-2028)
  • Table 209. Germany Phenylketonuria, by End User USD Million (2023-2028)
  • Table 210. France Phenylketonuria, by Type USD Million (2023-2028)
  • Table 211. France Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 212. France Phenylketonuria, by Test USD Million (2023-2028)
  • Table 213. France Phenylketonuria, by End User USD Million (2023-2028)
  • Table 214. Italy Phenylketonuria, by Type USD Million (2023-2028)
  • Table 215. Italy Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 216. Italy Phenylketonuria, by Test USD Million (2023-2028)
  • Table 217. Italy Phenylketonuria, by End User USD Million (2023-2028)
  • Table 218. United Kingdom Phenylketonuria, by Type USD Million (2023-2028)
  • Table 219. United Kingdom Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 220. United Kingdom Phenylketonuria, by Test USD Million (2023-2028)
  • Table 221. United Kingdom Phenylketonuria, by End User USD Million (2023-2028)
  • Table 222. Netherlands Phenylketonuria, by Type USD Million (2023-2028)
  • Table 223. Netherlands Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 224. Netherlands Phenylketonuria, by Test USD Million (2023-2028)
  • Table 225. Netherlands Phenylketonuria, by End User USD Million (2023-2028)
  • Table 226. Rest of Europe Phenylketonuria, by Type USD Million (2023-2028)
  • Table 227. Rest of Europe Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 228. Rest of Europe Phenylketonuria, by Test USD Million (2023-2028)
  • Table 229. Rest of Europe Phenylketonuria, by End User USD Million (2023-2028)
  • Table 230. MEA Phenylketonuria, by Country USD Million (2023-2028)
  • Table 231. MEA Phenylketonuria, by Type USD Million (2023-2028)
  • Table 232. MEA Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 233. MEA Phenylketonuria, by Test USD Million (2023-2028)
  • Table 234. MEA Phenylketonuria, by End User USD Million (2023-2028)
  • Table 235. Middle East Phenylketonuria, by Type USD Million (2023-2028)
  • Table 236. Middle East Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 237. Middle East Phenylketonuria, by Test USD Million (2023-2028)
  • Table 238. Middle East Phenylketonuria, by End User USD Million (2023-2028)
  • Table 239. Africa Phenylketonuria, by Type USD Million (2023-2028)
  • Table 240. Africa Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 241. Africa Phenylketonuria, by Test USD Million (2023-2028)
  • Table 242. Africa Phenylketonuria, by End User USD Million (2023-2028)
  • Table 243. North America Phenylketonuria, by Country USD Million (2023-2028)
  • Table 244. North America Phenylketonuria, by Type USD Million (2023-2028)
  • Table 245. North America Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 246. North America Phenylketonuria, by Test USD Million (2023-2028)
  • Table 247. North America Phenylketonuria, by End User USD Million (2023-2028)
  • Table 248. United States Phenylketonuria, by Type USD Million (2023-2028)
  • Table 249. United States Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 250. United States Phenylketonuria, by Test USD Million (2023-2028)
  • Table 251. United States Phenylketonuria, by End User USD Million (2023-2028)
  • Table 252. Canada Phenylketonuria, by Type USD Million (2023-2028)
  • Table 253. Canada Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 254. Canada Phenylketonuria, by Test USD Million (2023-2028)
  • Table 255. Canada Phenylketonuria, by End User USD Million (2023-2028)
  • Table 256. Mexico Phenylketonuria, by Type USD Million (2023-2028)
  • Table 257. Mexico Phenylketonuria, by Treatment USD Million (2023-2028)
  • Table 258. Mexico Phenylketonuria, by Test USD Million (2023-2028)
  • Table 259. Mexico Phenylketonuria, by End User USD Million (2023-2028)
  • Table 260. Phenylketonuria: by Type(USD/Units)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Phenylketonuria: by Type USD Million (2017-2022)
  • Figure 5. Global Phenylketonuria: by Treatment USD Million (2017-2022)
  • Figure 6. Global Phenylketonuria: by Test USD Million (2017-2022)
  • Figure 7. Global Phenylketonuria: by End User USD Million (2017-2022)
  • Figure 8. South America Phenylketonuria Share (%), by Country
  • Figure 9. Asia Pacific Phenylketonuria Share (%), by Country
  • Figure 10. Europe Phenylketonuria Share (%), by Country
  • Figure 11. MEA Phenylketonuria Share (%), by Country
  • Figure 12. North America Phenylketonuria Share (%), by Country
  • Figure 13. Global Phenylketonuria: by Type USD/Units (2017-2022)
  • Figure 14. Global Phenylketonuria share by Players 2022 (%)
  • Figure 15. Global Phenylketonuria share by Players (Top 3) 2022(%)
  • Figure 16. Global Phenylketonuria share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Agios Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Agios Pharmaceuticals Inc. (United States) Revenue: by Geography 2022
  • Figure 20. BioMarin Pharmaceutical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. BioMarin Pharmaceutical Inc. (United States) Revenue: by Geography 2022
  • Figure 22. Nestlé Health Science (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Nestlé Health Science (Switzerland) Revenue: by Geography 2022
  • Figure 24. American Gene Technologies International Inc (United States) Revenue, Net Income and Gross profit
  • Figure 25. American Gene Technologies International Inc (United States) Revenue: by Geography 2022
  • Figure 26. Mead Johnson & Company, LLC. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Mead Johnson & Company, LLC. (United States) Revenue: by Geography 2022
  • Figure 28. Danone Nutricia (Netherlands) Revenue, Net Income and Gross profit
  • Figure 29. Danone Nutricia (Netherlands) Revenue: by Geography 2022
  • Figure 30. Ajinomoto Cambrooke, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Ajinomoto Cambrooke, Inc. (United States) Revenue: by Geography 2022
  • Figure 32. Dr. Schär (Italy) Revenue, Net Income and Gross profit
  • Figure 33. Dr. Schär (Italy) Revenue: by Geography 2022
  • Figure 34. Promin Metabolics (United States) Revenue, Net Income and Gross profit
  • Figure 35. Promin Metabolics (United States) Revenue: by Geography 2022
  • Figure 36. PKU Perspectives (United States) Revenue, Net Income and Gross profit
  • Figure 37. PKU Perspectives (United States) Revenue: by Geography 2022
  • Figure 38. Global Phenylketonuria: by Type USD Million (2023-2028)
  • Figure 39. Global Phenylketonuria: by Treatment USD Million (2023-2028)
  • Figure 40. Global Phenylketonuria: by Test USD Million (2023-2028)
  • Figure 41. Global Phenylketonuria: by End User USD Million (2023-2028)
  • Figure 42. South America Phenylketonuria Share (%), by Country
  • Figure 43. Asia Pacific Phenylketonuria Share (%), by Country
  • Figure 44. Europe Phenylketonuria Share (%), by Country
  • Figure 45. MEA Phenylketonuria Share (%), by Country
  • Figure 46. North America Phenylketonuria Share (%), by Country
  • Figure 47. Global Phenylketonuria: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Agios Pharmaceuticals Inc. (United States)
  • BioMarin Pharmaceutical Inc. (United States)
  • Nestlé Health Science (Switzerland)
  • American Gene Technologies International Inc (United States)
  • Mead Johnson & Company, LLC. (United States)
  • Danone Nutricia (Netherlands)
  • Ajinomoto Cambrooke, Inc. (United States)
  • Dr. Schär (Italy)
  • Promin Metabolics (United States)
  • PKU Perspectives (United States)
Additional players considered in the study are as follows:
Censa Pharmaceuticals Inc. (United States) , Erytech Pharma SA (France)
Select User Access Type

Key Highlights of Report


Mar 2023 227 Pages 56 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Phenylketonuria Quantitative research analysis
Global Phenylketonuria Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Agios Pharmaceuticals Inc. (United States), BioMarin Pharmaceutical Inc. (United States), Nestlé Health Science (Switzerland), American Gene Technologies International Inc (United States), Mead Johnson & Company, LLC. (United States), Danone Nutricia (Netherlands), Ajinomoto Cambrooke, Inc. (United States), Dr. Schär (Italy), Promin Metabolics (United States) and PKU Perspectives (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Phenylketonuria Market during projected period 2022-2028.
The Phenylketonuria market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Phenylketonuria Report?

Have a Query? Click Here

Other Related Reports

Latex Gloves Comprehensive Study by Type (Powdered, Powder-free), Application (Hospital & Clinics, Laboratories, Food Handling, Others), Distribution Channel (Offline, Online), Industrial Verticals ...
$ 3800
Next-Generation Network Comprehensive Study by Application (Multimedia Services, Data Communication Services, PSTN/ISDN Simulation Services, PSTN/ISDN Emulation Services, Public Interest Services), C...
$ 3800
RF Power Detector Comprehensive Study by Type (Non-RMS power detectors, RMS power detectors), Application (Rugged Devices, Smartphones, Tablets), Industry Vertical (Telecommunications, Consumer Elect...
$ 3450
Convergent Billing Comprehensive Study by Application (Fixed, Mobile, Broadband, TV), Services (Managed Services, Consulting Services, Customized Services), Solutions (Customer Relationship Managemen...
$ 3650
Automotive Piston Pin Comprehensive Study by Type (Steel, Aluminum, Titanium, Others), Distribution Channels (OEM, Aftermarket), Coatings (DLC Coatings, PVD Coatings, Dry Film Lubricants, Oil Sheddin...
$ 3450
Telecom Power System Comprehensive Study by Type (Outdoor, Indoor, High Pressure, Slow Pressure, Atmospheric Pressure), Application (Communications Operators, Enterprise, Others), Power System (DC Po...
$ 3750